Wednesday November 25 2009 | Biotechnology feed | All feeds

BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

QLT Inc.

Formed in 1981. Became a public company in 1986. FOUNDERS Founded by a group of University of British Columbia professors, including Dr. Julia Levy who served as the Company's President and CEO from 1995 to 2002. EMPLOYEES About 485 professionals located in Vancouver, BC or Fort Collins, CO in the fields of science, research, manufacturing, technology and businessQLT is a global biopharmaceutical company specializing in developing treatments for cancer, eye diseases and dermatological and urological conditions. We have combined our expertise in the discovery, development, commercialization and manufacture of innovative drug therapies with our unique technology platforms to create highly successful products such as Visudyne® and Eligard®.


Contact Details:
887 Great Northern Way
Vancouver
British Columbia
V5T 4T5
Canada
Tel:604.707.7179
Fax:
Email:corpcomm@qltinc.com
WWW:

www.qltinc.com/




Loading...

Recent Publications by QLT Inc.:

Photodynamic therapy in immune (non-oncological) disorders: focus on benzoporphyrin derivatives.
This review examines the efficacy of photodynamic therapy in the treatment...
24th November, 2007
QLT Inc., Vancouver, British Columbia, Canada. BioDrugs. 2000 Aug;14(2):127-35.
Lack of effect of sex and disease state on the pharmacokinetics of porfimer sodium.
BACKGROUND: Porfimer sodium is an agent used for photodynamic therapy...
12th May, 2007
QLT Inc, Vancouver, British Columbia, Canada. Clin Pharmacokinet. 2006;45(9):923-30.
Influence of interleukin-1alpha on androgen receptor expression and cytokine secretion by cultured human dermal papilla cells.
Dermal papilla cells (DPC) control the growth character of the hair...
12th December, 2006
Scientific Affairs: Dermatology, QLT Inc., 887 Great Northern Way, Exp Dermatol. 2006 Oct;15(10):784-93.
DOI Direct Link
Cellular and antitumor activity of a new diethylene glycol benzoporphyrin derivative (lemuteporfin).
A newly synthesized diethylene glycol functionalized chlorin-type...
14th June, 2006
QLT Inc., 887 Great Northern Way, Vancouver, BC, Canada, V5T 4T5. Photochem Photobiol. 2006 Jan-Feb;82(1):219-24.
DOI Direct Link
Rapid induction of apoptosis in human keratinocytes with the photosensitizer QLT0074 via a direct mitochondrial action.
QLT0074 is a newly introduced, porphyrin-derivative for use in...
15th April, 2004
Department of Preclinical Pharmacology, QLT Inc., 887 Great Northern Way, Apoptosis. 2003 Jun;8(3):269-75.

View more QLT Inc. research publications.

Press Releases on QLT Inc.:

BioPortfolio Logo
Immune Design Corp. Announces Appointment of Dr. Bruce L.A. Carter as Executive Chairman and Director 23rd November, 2009 Immune Design Corp.
SEATTLE, Nov. 23 /PRNewswire/ -- Immune Design Corp. (IDC) announced today that Dr. Bruce L.A. Carter has joined IDC as Executive Chairman. Dr. Carter has a successful track record in biotechnology
QLT Announces Share Repurchase Program 27th October, 2009 QLT Inc.
VANCOUVER, Oct. 27 /PRNewswire-FirstCall/ - QLT Inc. (NASDAQ: QLTI; TSX: QLT) ("QLT" or the "Company") today announced that its board of directors has authorized the repurchase of
QLT announces third quarter results for 2009 27th October, 2009 QLT Inc.
QLT SEPARATELY ANNOUNCES SHARE REPURCHASE PROGRAM VANCOUVER, Oct. 27 /PRNewswire-FirstCall/ - QLT Inc. (NASDAQ: QLTI; TSX: QLT) ("QLT" or the "Company") today reported financial
QLT restructures Visudyne(R) agreement 19th October, 2009 QLT Inc.
RECEIVES EXCLUSIVE U.S. RIGHTS AND WILL RECEIVE A ROYALTY ON SALES OUTSIDE THE U.S. VANCOUVER, Oct. 19 /PRNewswire-FirstCall/ - QLT Inc. (NASDAQ: QLTI; TSX: QLT) ("QLT" or the
QLT announces sale of QLT USA, Inc. for up to US$230 million 1st October, 2009 QLT Inc.
VANCOUVER, Oct. 1 /PRNewswire-FirstCall/ - QLT Inc. (NASDAQ: QLTI; TSX: QLT) ("QLT" or the "Company") today announced that it has completed the sale of all of the shares of its

BioNews Results for QLT Inc.:

QLT Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile - new report released
PR inside:  Nov 13 2009 11:00AM Matching: qlt inc
QLT announces Toronto Stock Exchange approval of share repurchase program
SmartBrief:  Oct 29 2009 12:47AM Matching: qlt inc
BUYINS.NET: GSK, RGS, ABAX, UNF, SFN, QLTI Expected To Be Lower Leading Up To Next Earnings Releases
Individual.com:  Oct 28 2009 1:47AM Matching: qlt inc
QLT Announces Share Repurchase Program
SmartBrief:  Oct 27 2009 3:57PM Matching: qlt inc
QLT announces third quarter results for 2009
SmartBrief:  Oct 27 2009 4:59PM Matching: qlt inc
Promote your company here: BioNewsCast - Press Release Distribution

View more QLT Inc. news.

QLT Inc. Patents:

US Patent No.Title
7504228 Integrin linked kinase modulation of monocyte activation
6830925 CaMK-X1 and its uses
6800086 Reduced fluence rate PDT
6756396 Ethylene glycol esters as photoactive agents
6677366 Methods, compositions and articles for reducing or preventing the effects of inflammation

View more QLT Inc. patents.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 275 times since April 2007, the link to the organisation's website has been followed 43 times

Recent Search Terms used to find this page: qlt inc | .

Search for more companies in Vancouver

Search for more companies in British Columbia



This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for QLT Inc.

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997-2009 - BioPortfolio Limited.